Acquisition of Services Related to Compound 21 and In Vivo Pharmacokinetics Studies
Closed Pre-Solicitation Posted
- Solicitation number
- NICHD-23-231
- Agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Bethesda, Maryland 20892, United States
Notice details come from SAM.gov. Updated .
Notice text
The objective of the research is to advance the testing of compound 21 to determine its ability to become a new treatment for HIV infection. To properly make the molecule for this work, the lab must have the molecule synthesis in sufficient quantities to test in animals. Using the procedures provided by the NIDDK chemists, the company must scale up the production of compound 21 and deliver 10 g to the NIDDK lab. The compound 21 produced must also be tested for pharmacokinetics in rats and mice, and its metabolism studied. Results from each set of tests done are added to the file that will eventually be submitted for FDA approval as an investigational new drug. The continuity of the project is enhanced using as few CRO’s as possible and only ones technically qualified to meet the specific needs of the research.
Files
| File | Type | Posted |
|---|---|---|
| FRONTAGE LABORATORIES.NOTICE OF INTENT.NICHD-23-231.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity